Large-scale real-world data analysis reveals no single antidepressant consistently outperforms others across all outcomes. However, fluvoxamine and venlafaxine showed higher rates of discontinuation, augmentation needs, and psychiatric hospitalization in older adults.

Research findings favor augmentation over switching strategies in treatment-resistant depression. Aripiprazole augmentation showed superior efficacy and lower fall rates compared to other approaches in older adults.